Form D · Biotechnology
Onconetix, Inc.
Cincinnati, OH · CIK 0001782107
Offering snapshot reported Oct 7, 2025 · SEC filing
- Reported sold
- $13M Offering amount: $13M
- Investors reported
- 11 Form D · investor count
- Minimum accepted
- $209K Reported outside-investor minimum
- First sale
- Sep 22, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 7, 2025 | Initial | $12,977,670 | No comparison | 11 | SEC filing |
| Oct 17, 2024 | Initial | $2,000,000 | No comparison | 5 | SEC filing |
| Jul 15, 2019 | Initial | $6,979,980 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Equity, Debt, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-560082
Source: Form D, filed Oct 7, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Karina Fedasz | Executive |
| Joseph Hernandez | Executive |
| Thomas Meier | Director |
| Andrew Oakley | Director |
| Timothy Ramdeen | Director |
| James Sapirstein | Director |
| Ralph Schiess | Executive |
| Ajit Singh | Director |
| Simon Tarsh | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
201 E. Fifth Street Suite 1900
Cincinnati, OH, 45202
Cincinnati, OH, 45202